|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment显示文摘In patients with inflammatory bowel disease(IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporadic colorectal carcinoma and the critical molecular mechanisms underlying this process have yet to be elucidated. Patients with IBD have also been shown to be at increased risk of developing extra-intestinal malignancies. Medical therapies that diminish the mucosal inflammatory response represent the foundation of treatment in IBD, and recent evidence supports their introduction earlier in the disease course. However, therapies that alter the immune system, often used for long durations, may also promote carcinogenesis. As the population of patients with IBD grows older, with longer duration of chronic inflammation and longer exposure to immunosuppression, there is an increasing risk of cancer development. Many of these patients will require cancer treatment, including chemotherapy, radiation, hormonal therapy, and surgery. Many patients will require further treatment for their IBD. This review seeks to explore the characteristics and risks of cancer in patients with IBD, and to evaluate the limited data on patients with IBD and cancer, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of IBD and medications for IBD on cancer outcomes. | Jordan E Axelrad Simon Lichtiger Vijay Yajnik | 2016 | World Journal of Gastroenterology2016，22，20： | 33 |
| 2 | Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective显示文摘The use of thiopurines in inflammatory bowel disease(IBD) has been examined in numerous prospective, controlled trials, with a majority demonstrating a clinical benefit. We conducted this review to describe the historical and current evidence in the use of thiopurines in IBD. A systematic search was performed on MEDLINE between 1965 and 2016 to identify studies on thiopurines in IBD. The most robust evidence for thiopurines in IBD includes induction of remission in combination with anti-tumor necrosis factor(antiTNF) agents, and maintenance of remission and postoperative maintenance in Crohn's disease. Less evidence exists for thiopurine monotherapy in induction of remission, maintenance of ulcerative colitis, chemoprevention of colorectal cancer, and in preventing immunogenicity to anti-TNF. Evidence was often limited by trial design. Overall, thiopurines have demonstrated efficacy in a broad range of presentations of IBD. With more efficacious novel therapeutic agents, the positioning of thiopurines in the management of IBD will change and future studies will analyze the benefit of thiopurines alone and in conjunction with these new medications. | Jordan E Axelrad Abhik Roy Garrett Lawlor Burton Korelitz Simon Lichtiger | 2016 | World Journal of Gastroenterology2016，22，46： | 3 |
| 3 | Erythrocytic Sedimentation Rate as a Measure of Clinical Activity in Inflammatory Bowel Disease显示文摘 | David B. Sachar Harry Smith Simon Chan Lawrence B. Cohen Simon Lichtiger Julio Messer | 1986 | Journal of Clinical Gastroenterology1986，，6： | 1 |
| 4 | Mucosal Dysplasia in Ileal Pelvic Pouches After Restorative Proctocolectomy显示文摘 | Naris Nilubol Ellen Scherl David S. Bub Stephen R. Gorfine James Marion Michael T. Harris Asher Kornbluth Simon Lichtiger Peter Rubin James George Mark Chapman Noam Harpaz Daniel Present Joel J. Bauer | 2007 | Diseases of the Colon & Rectum2007，，6： | 1 |
| 5 | Efficacy of cyclosporine in treatment of fistula of crohn’s disease显示文摘 | Dr. Daniel H. Present MD Simon Lichtiger MD | 1994 | Digestive Diseases and Sciences1994，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员